A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for A

• Status: RECRUITING
• Trial end date: 2032-04-06

Summary

The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.

• Phase: PHASE3

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: belantamab mafodotin; daratumumab; Dexamethasone; Lenalidomide